TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
20 augusti, 14:00
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
PR Newswire
TAMPA, Fla., Aug. 20, 2025
TAMPA, Fla. , Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27 th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025 in New York City .
James Bianco , M.D., President and Chief Executive Officer of TuHURA Biosciences, is scheduled to present an overview and will be available for one-on-one meetings, as follows:
27 th Annual H.C. Wainwright Global Investment Conference | |
Date: | Monday, September 8, 2025 |
Time: | 2:30 PM Eastern Time |
Link: |
A replay of the presentation will be available on the Events page of the Investors section of the Company's website ( tuhurabio.com ). For more information about the event, please visit the conference website.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel therapies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in the merger with Kineta on June 30, 2025 . TBS-2025 is a VISTA inhibiting mAb asset moving into Phase 2 development in mutNPM1 r/r AML. In addition, TuHURA is leveraging its Delta Opiod Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook , X , and LinkedIn .
Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
SOURCE TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
20 augusti, 14:00
TuHURA Biosciences, Inc. to Present at the 27th Annual H.C. Wainwright Global Investment Conference
PR Newswire
TAMPA, Fla., Aug. 20, 2025
TAMPA, Fla. , Aug. 20, 2025 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA"), a Phase 3 immune-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that management will present at the 27 th Annual H.C. Wainwright Global Investment Conference taking place September 8-10, 2025 in New York City .
James Bianco , M.D., President and Chief Executive Officer of TuHURA Biosciences, is scheduled to present an overview and will be available for one-on-one meetings, as follows:
27 th Annual H.C. Wainwright Global Investment Conference | |
Date: | Monday, September 8, 2025 |
Time: | 2:30 PM Eastern Time |
Link: |
A replay of the presentation will be available on the Events page of the Investors section of the Company's website ( tuhurabio.com ). For more information about the event, please visit the conference website.
About TuHURA Biosciences, Inc.
TuHURA Biosciences, Inc. (Nasdaq: HURA) is a Phase 3 immuno-oncology company developing novel therapies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail to work or stop working in the majority of patients with cancer.
In addition to its innate immune agonist product candidates, TuHURA acquired TBS-2025 in the merger with Kineta on June 30, 2025 . TBS-2025 is a VISTA inhibiting mAb asset moving into Phase 2 development in mutNPM1 r/r AML. In addition, TuHURA is leveraging its Delta Opiod Receptor technology to develop first-in-class, bi-specific antibody drug conjugates and antibody peptide conjugates targeting Myeloid Derived Suppressor Cells to inhibit their immune-suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
For more information, please visit www.tuhurabio.com and connect with TuHURA on Facebook , X , and LinkedIn .
Investor Contact:
Monique Kosse
Gilmartin Group
Monique@GilmartinIR.com
SOURCE TuHURA Biosciences, Inc.
Analys
-950x950.webp&w=3840&q=75)
Nibes kvartal
Aktierekommendationer
.jpg&w=3840&q=75)
Aktier
Analys
Nibes kvartal
Aktierekommendationer
Aktier
Marknadsöversikt
1 DAG %
Senast
1 mån
%2520(1).jpg&w=3840&q=75)
.jpg&w=3840&q=75)